• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Two European firms ally in PET

Article

Alliance Medical of Oxfordshire and M2i of Dublin have formed a joint venture to produce and distribute PET radiopharmaceuticals in the U.K. The new company, called Molecular Imaging Services, will focus on the production of F-18 FDG (fluorodeoxyglucose)

Alliance Medical of Oxfordshire and M2i of Dublin have formed a joint venture to produce and distribute PET radiopharmaceuticals in the U.K. The new company, called Molecular Imaging Services, will focus on the production of F-18 FDG (fluorodeoxyglucose) through a series of dedicated radiopharmaceutical production units. These units will serve both hospital-based PET facilities and mobile PET scanners. Alliance Medical operates two PET scanners in the U.K.: a stationary unit at a facility located in London and a mobile PET scanner serving three hospitals. The mobile PET will soon begin serving a fourth hospital.

Recent Videos
Computed Tomography Study Shows Emergence of Silicosis in Engineered Stone Countertop Workers
Can an Emerging AI Software for DBT Help Reduce Disparities in Breast Cancer Screening?
Skeletal Muscle Loss and Dementia: What Emerging MRI Research Reveals
Magnetoencephalopathy Study Suggests Link Between Concussions and Slower Aperiodic Activity in Adolescent Football Players
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Can 18F-Floutufolastat Bolster Detection of PCa Recurrence in Patients with Low PSA Levels After Radical Prostatectomy?
Related Content
© 2024 MJH Life Sciences

All rights reserved.